ECP-1014 Treatment for Patients With Solid Tumor Cancers
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety, tolerability,
pharmacokinetics, and optimal recommended Phase 2 dose (RP2D) during a 28-day dosing period
of ECP-1014 in patients with solid tumors and by evaluation of dose limiting toxicities.